Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of 9MW2821 versus investigator's choice chemotherapy in previously treated unresectable locally advanced or metastatic urothelial carcinoma
CTR20234024Phase 3Active
- Sponsor
- Mabwell
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bulumtatug fuvedotin in transitional cell carcinoma (TCC), sponsored by Mabwell. Started Dec 2023; status: active.
02
Drugs
bulumtatug fuvedotin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20234024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234024.